WO2014072930A3 - Fused pyridine derivatives as antibacterial agents - Google Patents

Fused pyridine derivatives as antibacterial agents Download PDF

Info

Publication number
WO2014072930A3
WO2014072930A3 PCT/IB2013/059972 IB2013059972W WO2014072930A3 WO 2014072930 A3 WO2014072930 A3 WO 2014072930A3 IB 2013059972 W IB2013059972 W IB 2013059972W WO 2014072930 A3 WO2014072930 A3 WO 2014072930A3
Authority
WO
WIPO (PCT)
Prior art keywords
fabi
present
pyridine derivatives
fused pyridine
disorder
Prior art date
Application number
PCT/IB2013/059972
Other languages
French (fr)
Other versions
WO2014072930A2 (en
Inventor
Takhi Mohamed
Subramanya Hosahalli
Sunil Kumar Panigrahi
Original Assignee
Aurigene Discovery Technologies Limited
Um Pharmauji Sdn. Bhd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Technologies Limited, Um Pharmauji Sdn. Bhd filed Critical Aurigene Discovery Technologies Limited
Publication of WO2014072930A2 publication Critical patent/WO2014072930A2/en
Publication of WO2014072930A3 publication Critical patent/WO2014072930A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention relates to fused pyridine derivatives of formula (1) which may be therapeutically useful as as anti-bacterial agents, more particulalrly FabI inhibitors, in which P, Q, R1, R2, R3 and "n" have the same meanings given in the specification, and pharmaceutically acceptable salts and stereoisomers thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting Enoyl-ACP reductase enzyme (FABI) activity. The present invention also provides methods for synthesizing and administering the FabI inhibitory compounds. The present invention also provides pharmaceutical formulations comprising at least one of the FabI inhibitory compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
PCT/IB2013/059972 2012-11-09 2013-11-07 Fused pyridine derivatives as antibacterial agents WO2014072930A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN4705CH2012 2012-11-09
IN4705/CHE/2012 2012-11-09
IN2431CH2013 2013-06-03
IN2431/CHE/2013 2013-06-03

Publications (2)

Publication Number Publication Date
WO2014072930A2 WO2014072930A2 (en) 2014-05-15
WO2014072930A3 true WO2014072930A3 (en) 2014-07-31

Family

ID=50685270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/059972 WO2014072930A2 (en) 2012-11-09 2013-11-07 Fused pyridine derivatives as antibacterial agents

Country Status (1)

Country Link
WO (1) WO2014072930A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3317278B1 (en) 2015-07-01 2021-04-14 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2017136727A2 (en) 2016-02-05 2017-08-10 Denali Therapeutics Inc. Compounds, compositions and methods
ES2912295T3 (en) 2016-12-09 2022-05-25 Denali Therapeutics Inc Compounds useful as RIPK1 inhibitors
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
TW202334164A (en) 2022-01-12 2023-09-01 美商戴納立製藥公司 Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027103A1 (en) * 1999-10-08 2001-04-19 Smithkline Beecham Corporation Fab i inhibitors
CA2444597A1 (en) * 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
WO2004052890A1 (en) * 2002-12-06 2004-06-24 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
WO2004082586A2 (en) * 2003-03-17 2004-09-30 Affinium Pharmaceuticals, Inc. Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
CA2568914A1 (en) * 2004-06-04 2005-12-04 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
WO2008009122A1 (en) * 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
WO2008074413A2 (en) * 2006-12-20 2008-06-26 Sanofi-Aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial no synthase
WO2011061214A1 (en) * 2009-11-18 2011-05-26 Fab Pharma Sas Novel heterocyclic acrylamides and their use as pharmaceuticals
WO2013021051A1 (en) * 2011-08-10 2013-02-14 Janssen R&D Ireland Antibacterial homopiperidinyl substituted 3,4 dihydro 1h [1,8]naphthyridinones
WO2013021052A1 (en) * 2011-08-10 2013-02-14 Janssen R&D Ireland Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
WO2013080222A1 (en) * 2011-12-02 2013-06-06 Aurigene Discovery Technologies Limited Substituted pyridine derivatives as fabi inhibitors

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027103A1 (en) * 1999-10-08 2001-04-19 Smithkline Beecham Corporation Fab i inhibitors
CA2444597A1 (en) * 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
WO2004052890A1 (en) * 2002-12-06 2004-06-24 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
WO2004082586A2 (en) * 2003-03-17 2004-09-30 Affinium Pharmaceuticals, Inc. Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
CA2568914A1 (en) * 2004-06-04 2005-12-04 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
WO2008009122A1 (en) * 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
WO2008074413A2 (en) * 2006-12-20 2008-06-26 Sanofi-Aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial no synthase
WO2011061214A1 (en) * 2009-11-18 2011-05-26 Fab Pharma Sas Novel heterocyclic acrylamides and their use as pharmaceuticals
WO2013021051A1 (en) * 2011-08-10 2013-02-14 Janssen R&D Ireland Antibacterial homopiperidinyl substituted 3,4 dihydro 1h [1,8]naphthyridinones
WO2013021052A1 (en) * 2011-08-10 2013-02-14 Janssen R&D Ireland Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
WO2013080222A1 (en) * 2011-12-02 2013-06-06 Aurigene Discovery Technologies Limited Substituted pyridine derivatives as fabi inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAMES A. KARLOWSKY ET AL.: "In Vitro Activity of API-1252, a Novel FabI Inhibitor, against Clinical Isolates of Staphylococcus aureus and Staphylococcus epidermidis Antimicrobial.", AGENTS CHEMOTHERAPY, vol. 51, no. 4, April 2007 (2007-04-01), pages 1580 - 1581 *

Also Published As

Publication number Publication date
WO2014072930A2 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
PH12020500529A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
WO2014125408A3 (en) Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
PH12016501355B1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
WO2014106800A8 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
WO2014128669A3 (en) Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
SG11201408052WA (en) IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS
PH12014501469A1 (en) Bromodomain inhibitors
MX2013013692A (en) Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors.
MX2010007714A (en) Fused pyridines active as inhibitors of c-met.
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors
WO2012104263A3 (en) 1,4 oxazines as bace1 and/or bace2 inhibitors
WO2013004995A8 (en) Pyrimidinone compounds and their use
MX2019010096A (en) 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors.
MX2013014194A (en) Cyclopropyl-fused-1,3-thiazepines as bace 1 and/or bace 2 inhibitors.
WO2014072930A3 (en) Fused pyridine derivatives as antibacterial agents
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
IN2015MN00002A (en)
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
PH12015500012A1 (en) Benzodioxole derivative and preparation method and use thereof
MX2013002956A (en) Arylosulfonamides for the treatment of cns diseases.
WO2014141035A3 (en) Fused heterocyclyl derivatives as nampt inhibitors
WO2013106756A3 (en) Antimicrobial agents
AU2012225365A8 (en) Peptide deformylase inhibitors

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13852390

Country of ref document: EP

Kind code of ref document: A2